Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib, Tislelizumab, and TACE as Neoadjuvant for HCC
NCT05920863Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jul 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of lenvatinib, tislelizumab in hepatocellular carcinoma (HCC), sponsored by Zhejiang Cancer Hospital. Started Jul 2023; status: recruiting.
02
Drugs
lenvatinibtislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05920863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05920863.